Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much hope is attached to one event. For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), the question is whether a successful metabolic-disease trial can finally replace the failed ALS narrative that has defined the company since Relyvrio was withdrawn.
LUCIDITY randomized 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery in a 3:2 ratio to receive once-daily avexitide or placebo. The FDA-agreed primary outcome measures the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Avexitide is designed to block the exaggerated GLP-1 response that can drive excess insulin secretion and dangerous drops in blood glucose.
The trial is therefore more than another pipeline update. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) currently has no approved product, and avexitide is its most advanced near-term opportunity to rebuild a commercial business. A positive result would validate the company’s move into endocrine disease. A miss would return attention to earlier-stage programs that cannot replace a late-stage asset quickly.
BULL CASE: Earlier Studies Point in the Same Direction
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) enters the readout with supportive early evidence. Amylyx said five earlier Phase 1 and Phase 2 studies produced consistent signals. In a 28-day, open-label Phase 2b crossover study involving 16 patients who had undergone Roux-en-Y gastric bypass or other upper gastrointestinal surgeries, the 90 mg once-daily dose now used in LUCIDITY reduced Level 2 events by 53% and Level 3 events by 66% against the medical nutrition therapy-only run-in baseline. Avexitide was generally well tolerated across prior studies.
The FDA has granted avexitide Breakthrough Therapy designation for post-bariatric hypoglycemia, and management anticipates a potential 2027 launch if the drug is approved. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) held $250.8 million in cash, cash equivalents, and short-term investments as of June 30. Based on its current operating plans, Amylyx expects that amount to provide a cash runway into 2028, supporting a potential regulatory filing and commercial preparations.
BEAR CASE: A Small Trial Carries Most of the Valuation
The same concentration that creates upside also makes the setup fragile. With only 78 participants and one 16-week primary outcome, LUCIDITY must translate encouraging results from much smaller, shorter studies into a pivotal trial. Even a statistically positive headline could leave questions about effect size, safety, durability, or the FDA’s filing requirements.
That risk carries more weight because Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) withdrew Relyvrio in the United States and Canada in 2024 after the Phase 3 PHOENIX trial failed to confirm its ALS benefit. The readout will also test whether management’s confidence in the early evidence can survive a pivotal study.
INSIDER MONKEY’S HEDGE FUND DATA
The filings available so far reflect positions held before Amylyx scheduled the Phase 3 LUCIDITY results announcement. Insider Monkey’s first-quarter database showed 34 hedge funds holding Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) at the end of March 2026, down from 40 funds three months earlier.
CONCLUSION
Positive LUCIDITY results could allow Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) to emerge as a credible metabolic-disease company with a potential commercial launch in 2027. However, success must mean more than clearing a statistical threshold: the result must support a persuasive regulatory and commercial case.
The answer is conditional. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) can rebuild around avexitide, but the company has concentrated much of its near-term value in one small Phase 3 trial. That makes the opportunity meaningful and the risk unmistakably binary.
While we acknowledge the risk and potential of AMLX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMLX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center